<code id='B7B0C0FC54'></code><style id='B7B0C0FC54'></style>
    • <acronym id='B7B0C0FC54'></acronym>
      <center id='B7B0C0FC54'><center id='B7B0C0FC54'><tfoot id='B7B0C0FC54'></tfoot></center><abbr id='B7B0C0FC54'><dir id='B7B0C0FC54'><tfoot id='B7B0C0FC54'></tfoot><noframes id='B7B0C0FC54'>

    • <optgroup id='B7B0C0FC54'><strike id='B7B0C0FC54'><sup id='B7B0C0FC54'></sup></strike><code id='B7B0C0FC54'></code></optgroup>
        1. <b id='B7B0C0FC54'><label id='B7B0C0FC54'><select id='B7B0C0FC54'><dt id='B7B0C0FC54'><span id='B7B0C0FC54'></span></dt></select></label></b><u id='B7B0C0FC54'></u>
          <i id='B7B0C0FC54'><strike id='B7B0C0FC54'><tt id='B7B0C0FC54'><pre id='B7B0C0FC54'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:7
          3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT
          Adobe

          Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

          The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

          advertisement

          The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Gilead might be held responsible for not developing a drug
          Gilead might be held responsible for not developing a drug

          JustinSullivan/GettyImagesTheassaultonthedevelopmentofnewlifesavingtherapiescontinuesapace.Recently,

          read more
          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more

          BioAge raises $170M for combination therapy with Zepbound

          Illustration:STAT;Source:EliLilly/APACaliforniabiotechdevelopingacombinationtherapywiththeobesitydru